Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Advantage Alpha Capital Partners LP

Advantage Alpha Capital Partners LP reduced its position in Xencor, Inc. (NASDAQ:XNCR) by 42.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,861 shares of the biopharmaceutical company’s stock after selling 18,010 shares during the period. Advantage Alpha Capital Partners LP’s holdings in Xencor were worth $500,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of XNCR. Logos Global Management LP lifted its position in Xencor by 130.8% during the second quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company’s stock valued at $28,395,000 after buying an additional 850,000 shares in the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of Xencor by 52.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,261,789 shares of the biopharmaceutical company’s stock valued at $23,886,000 after acquiring an additional 436,389 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Xencor by 9.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock worth $84,530,000 after purchasing an additional 335,881 shares during the period. Vanguard Group Inc. increased its holdings in Xencor by 3.6% in the 1st quarter. Vanguard Group Inc. now owns 7,011,042 shares of the biopharmaceutical company’s stock valued at $155,154,000 after purchasing an additional 243,793 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new position in Xencor in the first quarter valued at about $4,608,000.

Insider Transactions at Xencor

In related news, VP John R. Desjarlais sold 68,684 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the completion of the transaction, the vice president now directly owns 200,104 shares in the company, valued at $4,698,441.92. This represents a 25.55 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Bassil I. Dahiyat sold 3,366 shares of the company’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $24.02, for a total transaction of $80,851.32. Following the transaction, the chief executive officer now owns 352,615 shares of the company’s stock, valued at $8,469,812.30. This represents a 0.95 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 121,328 shares of company stock worth $2,879,673. 5.23% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently weighed in on XNCR. BMO Capital Markets reaffirmed an “outperform” rating and issued a $34.00 target price (up previously from $32.00) on shares of Xencor in a research report on Friday, November 8th. Royal Bank of Canada increased their price objective on shares of Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a research report on Thursday, September 26th. Wedbush reiterated an “outperform” rating and set a $38.00 price objective on shares of Xencor in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. upped their target price on shares of Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $35.75.

Xencor Stock Down 2.9 %

Shares of NASDAQ:XNCR opened at $25.30 on Wednesday. The firm has a market cap of $1.77 billion, a PE ratio of -7.91 and a beta of 0.66. The company has a fifty day simple moving average of $21.57 and a 200 day simple moving average of $20.39. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor, Inc. has a 12-month low of $15.31 and a 12-month high of $26.84.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.98) by $0.27. The company had revenue of $10.70 million during the quarter, compared to analyst estimates of $14.59 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The firm’s revenue for the quarter was down 81.9% compared to the same quarter last year. During the same period last year, the business earned ($0.40) EPS. On average, equities research analysts anticipate that Xencor, Inc. will post -3.71 EPS for the current fiscal year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.